Modelling clustered survival data from multicentre clinical trials.
about
Artemether-lumefantrine treatment of uncomplicated Plasmodium falciparum malaria: a systematic review and meta-analysis of day 7 lumefantrine concentrations and therapeutic response using individual patient dataProspective association of a genetic risk score and lifestyle intervention with cardiovascular morbidity and mortality among individuals with type 2 diabetes: the Look AHEAD randomised controlled trial.Conditional and Marginal Estimates in Case-Control Family Data - Extensions and Sensitivity Analyses.Estimating length of stay in publicly-funded residential and nursing care homes: a retrospective analysis using linked administrative data sets.A framework for developing, implementing, and evaluating clinical prediction models in an individual participant data meta-analysis.Frailty modeling for clustered competing risks data with missing cause of failure.Multiple frailty model for clustered interval-censored data with frailty selection.The effect of dosing strategies on the therapeutic efficacy of artesunate-amodiaquine for uncomplicated malaria: a meta-analysis of individual patient dataBaseline data of parasite clearance in patients with falciparum malaria treated with an artemisinin derivative: an individual patient data meta-analysis.A multilevel excess hazard model to estimate net survival on hierarchical data allowing for non-linear and non-proportional effects of covariates.Bias and precision of methods for estimating the difference in restricted mean survival time from an individual patient data meta-analysis.Investigating covariate-by-centre interaction in survival data.Adjusting for multiple prognostic factors in the analysis of randomised trialsSemi-parametric risk prediction models for recurrent cardiovascular events in the LIPID studyIncreased age-associated mortality risk in HLA-mismatched hematopoietic stem cell transplantation.A positive stable frailty model for clustered failure time data with covariate-dependent frailty.Genes contributing to prion pathogenesisMethods for Estimating Center Effects on Recurrent Events.Comparing methods to estimate treatment effects on a continuous outcome in multicentre randomized controlled trials: a simulation studyFrailty modelling for survival data from multi-centre clinical trialsA competing risks model for correlated data based on the subdistribution hazard.A Gaussian Copula Model for Multivariate Survival DataThe revolving door phenomenon revisited: time to readmission in 17’145 [corrected] patients with 37'697 hospitalisations at a German psychiatric hospital.The trade-off between costs and outcomes: the case of acute myocardial infarctionSuperior survival using living donors and donor-recipient matching using a novel living donor risk index.Plasmodium vivax recurrence following falciparum and mixed species malaria: risk factors and effect of antimalarial kinetics.A Multiresolution Hazard Model for Multicenter Survival Studies: Application to Tamoxifen Treatment in Early Stage Breast Cancer.Accounting for centre-effects in multicentre trials with a binary outcome - when, why, and how?The effect of dose on the antimalarial efficacy of artemether-lumefantrine: a systematic review and pooled analysis of individual patient data.A Comparison of Seven Cox Regression-Based Models to Account for Heterogeneity Across Multiple HIV Treatment Cohorts in Latin America and the CaribbeanSurgical risks associated with winter sport tourismCD4 cell count and the risk of AIDS or death in HIV-Infected adults on combination antiretroviral therapy with a suppressed viral load: a longitudinal cohort study from COHEREIs there a race-based disparity in the survival of veterans with HIV?Effect of telehealth on use of secondary care and mortality: findings from the Whole System Demonstrator cluster randomised trial.Cohort Multiple Randomised Controlled Trials (cmRCT) design: efficient but biased? A simulation study to evaluate the feasibility of the Cluster cmRCT design.Impact of Donor Activating KIR Genes on HSCT Outcome in C1-Ligand Negative Myeloid Disease Patients Transplanted with Unrelated Donors-A Retrospective Study.Prospective Association of GLUL rs10911021 With Cardiovascular Morbidity and Mortality Among Individuals With Type 2 Diabetes: The Look AHEAD Study.Observational Studies: Matching or Regression?Analysis of time-to-event and duration outcomes in neonatal clinical trials with twin births.Effect of telecare on use of health and social care services: findings from the Whole Systems Demonstrator cluster randomised trial.
P2860
Q26783646-6B0E0995-E93D-4BCB-A28F-57E9460FB0D8Q27325816-D1651DEE-583A-481C-A2EC-D3EBD3E296F0Q30570220-6B915753-5365-4D4E-B1BB-671575CABC88Q30575360-141A2640-8EAE-4D2D-BE03-566DEF7A1172Q30585625-8CF653E0-12CF-46F5-927C-937E2286F6AEQ30842928-1430C474-29F3-4D40-A068-027A73966DD6Q30913392-723000E4-B7F6-4941-ADDC-F3EBAB25FFDDQ30936416-4CED1293-C49A-4CB2-A35B-49C7E0AFFADEQ30995133-DBDAC70B-A5C5-407E-BF9D-F65BEFAAD887Q31049883-3F829E74-4F58-4E19-96C4-55A9E496FD41Q31064714-BD7B71D6-C28F-4E5A-A4F3-ACF4FC73C29FQ31095303-BBD0D58A-E2BE-4017-BF8B-6F46D0302641Q31124574-B246FD76-7C7D-4E23-B0DD-F22044D3EFDBQ33548159-94656FDD-483A-4BFD-AD9C-6EEF4CC70DA5Q33574209-7C3C6C3D-45B1-4FF8-BB14-DA9D6FE20F8AQ33596499-4A324868-5ADC-4C2C-BD64-8D81008ED673Q33687685-F72FBEB9-961B-4F32-8031-AD105DD5E5B2Q33811473-019CC180-5427-4FB1-9405-30C351DE2A06Q33825817-F962E870-ECC9-477D-AB16-7556B79A5915Q33896208-D8EED235-BBF0-4D52-8B87-CF5523B2BE94Q33908677-07D2DAC8-7A41-4AFE-BF76-627674413C91Q34097546-037A00C6-334B-4EBA-8D8C-80B2329CB1C2Q34377063-CB727482-39E6-48BC-BB4C-9601A83D293AQ34381408-43B77CA0-CB40-480B-BD90-A4B319C7992EQ34415850-EA3C2CDC-6A1C-45C4-917B-C3AADEE02CF7Q34699136-4EBAD913-0392-4203-B347-2CCF34470E00Q34999425-06FFA1FE-F06D-4DCC-85BB-CDA8F3A64716Q35089861-E49E21C7-AA2A-4FBB-BC08-B11585AC9F37Q35580908-7618BAEC-7098-4077-BD33-AF943BC849A1Q35589775-9E49AED9-4516-4D86-AFE9-E540ABB47A0BQ35602178-D0A6A3AE-9E7F-4683-A37F-5B7F274EA56AQ35842386-853BDE84-AD63-488A-9FDB-63B0DCC8E46FQ35901340-7AED7DE4-575F-4424-9665-7CE3D9378936Q36052086-1596EC1F-6745-4265-BC1F-C79541DF01A4Q36114940-14625D19-8476-4C1B-AC6A-D5ADDB74711BQ36255385-9D93C673-9A7B-43FB-A42B-1B9C587F1645Q36392873-F85613CE-BE15-43FB-B248-D37C1EFCF176Q36587971-E0109022-422A-43ED-9701-E2AF2CF38CDAQ36712116-11CD0F94-2800-4206-AC30-D90992A8F131Q36933493-9819D71E-7A07-430F-A429-BFD6F09FF318
P2860
Modelling clustered survival data from multicentre clinical trials.
description
2004 nî lūn-bûn
@nan
2004 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2004 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
name
Modelling clustered survival data from multicentre clinical trials.
@ast
Modelling clustered survival data from multicentre clinical trials.
@en
type
label
Modelling clustered survival data from multicentre clinical trials.
@ast
Modelling clustered survival data from multicentre clinical trials.
@en
prefLabel
Modelling clustered survival data from multicentre clinical trials.
@ast
Modelling clustered survival data from multicentre clinical trials.
@en
P356
P1476
Modelling clustered survival data from multicentre clinical trials.
@en
P2093
David V Glidden
P304
P356
10.1002/SIM.1599
P407
P577
2004-02-01T00:00:00Z